Press releases | WebDisclosure

Basculer en Français

10973	Companies
240348	Keywords
169092	Articles
129348	Press releases

Home
Press releases

PRESS RELEASE

published on 10/21/2024 at 14:30, 1 year 10 months ago

XS Financial Expands Into Middle-Market Equipment Finance, Establishing Buy-Side Capital Markets Desk
XS Financial announces strategic expansion into mid to large-ticket transactions in middle-market equipment leasing sector. Acquired by Axar and Mavik, enhancing financial strength and flexibility

Expansion Capital Markets Equipment Finance XS Financial Middle-Market
PRESS RELEASE

published on 10/21/2024 at 14:30, 1 year 10 months ago

LQR House Inc. Implements Strategic Cost-Cutting Measures Under Activist Investor David Lazar's Leadership
LQR House Inc. announces strategic updates including shutting down RareSips NFT platform and ending Bevage LLC partnership under new Director David Lazar to enhance operational efficiency and shareholder value

LQR House Inc. Operational Efficiency Shareholder Value Strategic Updates David Lazar
PRESS RELEASE

published on 10/21/2024 at 14:30, 1 year 10 months ago

Catheter Precision Announces Clinical Publication of Non-Invasive Stereotactic Radioablation Using VIVO
Catheter Precision announces publication on non-invasive ablation technique STAR for cardiac electrophysiology. VIVO technology shows promising results in targeting heart arrhythmia areas

Catheter Precision Cardiac Electrophysiology VIVO Technology STAR Ablation Technique
PRESS RELEASE

published on 10/21/2024 at 14:30, 1 year 10 months ago

Inventiva annonce un abstract « late breaker » sur l’essai clinique de Phase 2, LEGEND, combinant lanifibranor et empagliflozine, lors du Liver Meeting™ 2024 organisé par l’AASLD
Inventiva annonce un abstract "late breaker" sur l'essai clinique de Phase 2, LEGEND, combinant lanifibranor et empagliflozine lors du Liver Meeting™ 2024 organisé par l'AASLD

Essai Clinique Inventiva Lanifibranor Abstract Empagliflozine
PRESS RELEASE

published on 10/21/2024 at 14:30, 1 year 10 months ago

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Inventiva announces late breaker abstract from LEGEND Phase 2 trial evaluating lanifibranor with empagliflozin in MASH at AASLD The Liver Meeting® 2024

Inventiva MASH Lanifibranor LEGEND Phase 2 Empagliflozin
PRESS RELEASE

published on 10/21/2024 at 14:25, 1 year 10 months ago

Director/PDMR Shareholding
Britvic plc Directors purchase shares and receive matching shares under Share Incentive Plan. Details of transactions and interests disclosed

Transactions Share Incentive Plan Britvic Plc Directors Matching Shares
PRESS RELEASE

published on 10/21/2024 at 14:15, 1 year 10 months ago

Quant Tekel: Defining the Future of Trading
Quant Tekel revolutionizes brokerage and prop trading with cutting-edge technology, unmatched experience, and top-tier support for traders, offering opportunities for success and personal growth

Cutting-edge Technology Financial Markets Brokerage Prop Trading Quant Tekel
PRESS RELEASE

published on 10/21/2024 at 14:01, 1 year 10 months ago

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed reports 4% revenue increase in Mid-Year 2024 Financial Results with 32% decrease in loss from operations. Company highlights successful studies at ASCO and outlines strategic plan for 2025

Financial Results Corporate Update ColoAlert Mainz Biomed EAArly DETECT
PRESS RELEASE

published on 10/21/2024 at 14:00, 1 year 10 months ago

CANEX Increases Equity Financing
CANEX Metals Inc. announces increase in non-brokered private placement to offer up to 3,000,000 Common Shares and 5,250,000 FT Shares for a total of $450,000. Funds to be used for exploration and project advancement

Private Placement TSX Venture Exchange Exploration CANEX Metals Inc. Shareholder Demand
PRESS RELEASE

published on 10/21/2024 at 13:30, 1 year 10 months ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
MIRA Pharmaceuticals, Inc. announces promising results for novel oral ketamine analog Ketamir-2 in providing superior pain relief compared to current treatments. Preparing for Phase 1 clinical trials and exploring potential in PTSD

Clinical Trials PTSD MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain

Accesswire

Published on 09/14/2026 at 15:15, 52 minutes ago

Mako Mining Announces a Non-Binding Letter of Intent to Enter a Gold Purchase Agreement with Sailfish Royalty to Lower its Cost of Capital and Facilitate Shareholder Returns and Accretive Acquisitions
Published on 09/14/2026 at 15:00, 1 hour 7 minutes ago

Vox Royalty Completes Acquisitions of White Dam, Kalman and Sylvania Australian Gold & Copper Royalties
Published on 09/14/2026 at 14:30, 1 hour 37 minutes ago

Goldcliff Finalizes Drill Plans for New East Breccia Gold-Silver Target at Kettle Valley
Published on 09/14/2026 at 14:00, 2 hours 7 minutes ago

Revolve Completes Acquisition of 9.6 MW Operating Wind Project in the US
Published on 09/14/2026 at 14:00, 2 hours 7 minutes ago

Kinross Encounters Gold and Copper in Recent Drill Holes with Gold Values up to 6 g/t, Kinross Drilling to Continue on Dixie Halo

View all ACCESSWIRE

EQS Group

Published on 09/14/2026 at 15:58, 8 minutes ago

Sanofi and Cheplapharm to create new strategic partnership in mature medicines
Published on 09/14/2026 at 15:26, 41 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 09/14/2026 at 15:25, 41 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 09/14/2026 at 15:25, 42 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 09/14/2026 at 15:23, 43 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Rotork plc

Les Echos

Published on 09/11/2026 at 07:00, 3 days 9 hours ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 3 days 9 hours ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 3 days 9 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 3 days 9 hours ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 3 days 20 hours ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE